2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Gene Therapy, Biological Processes, Apoptosis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Immunology, Autoimmune Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, CML, Study Population, Human, Animal Model
PAPER

3121 PRSS2 is an oxygen-responsive regulator of human hematopoietic stem cell potency and engraftment

Jimin Park, PhD, Erin Keith Gray2, So Jeong Kim3, Jessica Newton4, Nikhil Nayak5, Sarah Gutch, PhD6, Lindsay Wathen, MSc7, Maegan Capitano, PhD8, Yann Gibert, Ph.D.9, James Ropa, PhD10
1 Indiana University School of Medicine, Indianapolis, Indiana, United States
2 Indiana University School of Medicine, Indianapolis, Indiana, United States
3 Indiana University School of Medicine, Indianapolis, Indiana, United States
4 Indiana University School of Medicine, Indianapolis, Indiana, United States
5 Indiana University School of Medicine, Indianapolis, Indiana, United States
6 Indiana University School of Medicine, Indianapolis, Indiana, United States
7 Indiana University School of Medicine, Indianapolis, Indiana, United States
8 Indiana University School of Medicine, Indianapolis, Indiana, United States
9 Indiana University School of Medicine, Indianapolis, Indiana, United States
10 Indiana University School of Medicine, Indianapolis, Indiana, United States
Background: Hematopoietic stem and progenitor cells (HSPCs) reside in physiologically low-oxygen environments, but the genes that maintain HSPC function under these conditions are not fully understood. Using single-cell transcriptomics, we have identified PRSS2, which encodes the serine protease Trypsin-2, as an oxygen-responsive gene enriched in primitive human HSPCs. Further integration of bulk transcriptomics with functional mouse analyses demonstrated that PRSS2 expression was also associated with increased long-term SCID-repopulating cell (SRC) frequency, suggesting a relationship between PRSS2 expression and HSPC functional potency. Trypsin-2 is primarily produced by the pancreas and is best known as a digestive protease, making its expression and potential function in hematopoietic cells unexpected. PRSS2 expression is also changed in hematologic disease, including reduced expression in aplastic anemia, further suggesting a relationship between PRSS2 and hematopoietic function. Here, we investigated the functional role of PRSS2 in human HSPCs across different oxygen conditions and its contribution to hematopoietic engraftment. 
Methods: Human umbilical cord blood CD34+ cells were maintained at 1% or 21% O2 and treated with control or PRSS2-targeting siRNA before transplantation into immunodeficient mice. Human hematopoietic reconstitution was assessed by peripheral blood and bone marrow human CD45+ chimerism and immunophenotypic analysis of bone marrow HSC and progenitor populations. PRSS2 mRNA and protein expression in CD34+ cells cultured at 1%, 5%, 10%, and 21% O2 were assessed by qPCR and quantitative confocal immunofluorescence. As an independent genetic approach, cord blood CD34+ cells were targeted with CRISPR-Cas9 followed by HSPC immunophenotyping, apoptosis analysis, and colony-forming unit (CFU) assays. The effect of active human PRSS2 on hematopoiesis was also evaluated in zebrafish embryos using whole-mount in situ hybridization and qPCR.
Results: PRSS2 mRNA expression, measured by qPCR, was highest at 1% O2 and decreased with increasing oxygen tension. Consistent with these findings, quantitative confocal immunofluorescence demonstrated a corresponding reduction in PRSS2 protein abundance across 1%, 5%, 10%, and 21% O2, supporting oxygen-responsive regulation of PRSS2 in human CD34+ HSPCs. Mining of publicly available patient datasets showed that PRSS2 expression was decreased in CD34+ bone marrow cells from patients with aplastic anemia and partially recovered following immunosuppressive treatment. PRSS2 was also enriched in hematologic malignancies associated with poor clinical outcomes. Following culture at 1% O2, PRSS2 knockdown markedly impaired human hematopoietic reconstitution. At 16 weeks after transplantation, human CD45+ chimerism was significantly decreased in both peripheral blood and bone marrow. Bone marrow analysis also demonstrated a significant reduction in immunophenotypically defined HSCs, while most downstream progenitor populations were less affected. Conversely, ex vivo treatment with recombinant Trypsin-2 increased CD34+ cell expansion, additionally supporting a functional role for PRSS2 in human HSPCs. 
Next, we targeted PRSS2 using CRISPR-Cas9 as an independent genetic approach. CRISPR targeting reduced HSC frequency at both 1% and 21% O2 and reduced multipotent progenitor frequency under 1% O2. Under 1% O2, PRSS2 targeting also markedly increased the frequency of apoptotic cells, supporting a role for PRSS2 in HSPC survival under physiologic low oxygen. Consistent with these findings, PRSS2 targeting significantly decreased total colony-forming capacity and multilineage CFU-GEMM output under 1% O2. In an additional in vivo model, treatment of zebrafish embryos with active human PRSS2 significantly increased expression of the erythroid markers hbbe1 and gata1, supporting a role for PRSS2 in hematopoietic regulation.
Conclusions: Our findings identify PRSS2 as an unexpected regulator of human hematopoietic stem and progenitor cell function. PRSS2 is oxygen-responsive, associated with hematologic disease and HSPC potency, and is functionally important for HSPC survival, primitive HSPC maintenance, and hematopoietic engraftment. Independent CRISPR studies and zebrafish analyses moreover support a role for PRSS2 in hematopoietic regulation. Together, these data reveal a previously unrecognized function for the digestive protease Trypsin-2 in hematopoiesis. 
Jimin Park, PhD: No relevant conflicts of interest to declare.